Pharmacologic treatments for covid-19 patients

Bamlanivimab+Etesevimab (LY-CoV555+LY-CoV016) vs Placebo


Outpatients

Forest plots
(last update: 2022-02-25)

Summary of findings
(last update: 2022-03-31)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=254

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04427501
Dougan M, Clin Infect Dis, 2021
Full text
Commentary
Commentary
Private

LY-CoV555+LY-CoV016

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated at multiple centers in the USA and Puerto Rico. N=782
Low
Details

Full description

NCT04427501
BLAZE-1
Dougan M, N Engl J Med, 2021
Full text
Commentary
Private

LY-CoV555+LY-CoV016

Placebo

RCT Outpatients with confirmed COVID-19 (mild-moderate) treated at multiple centers in USA. N=1035
Some concerns
Details

Full description

NCT04427501
BLAZE-1
Gottlieb R, JAMA, 2021
Full text
Commentary
Commentary
Private

LY-CoV555 700 mg

LY-CoV555 700 mg

LY-CoV555+LY-CoV016

Placebo

LY-CoV555+LY-CoV016

Placebo

RCT Outpatients with COVID-19 (mild ambulatory) treated at 49 centers in USA N=592
Some concerns
Details

Full description